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Abstract Venous thromboembolism (VTE) is common
and has a high impact on morbidity, mortality, and costs of
care. Although most of the patients with VTE are aged
C65 years, there is little data about the medical outcomes
in the elderly with VTE. The Swiss Cohort of Elderly
Patients with VTE (SWITCO65?) is a prospective multi-
center cohort study of in- and outpatients aged C65 years
with acute VTE from all five Swiss university and four
high-volume non-university hospitals. The goal is to
examine which clinical and biological factors and pro-
cesses of care drive short- and long-term medical out-
comes, health-related quality of life, and medical resource
utilization in elderly patients with acute VTE. The cohort
also includes a large biobank with biological material from
each participant. From September 2009 to March 2012,
1,863 elderly patients with VTE were screened and 1003
(53.8 %) were enrolled in the cohort. Overall, 51.7 % of
patients were aged C75 years and 52.7 % were men. By
October 16, 2012, after an average follow-up time of
512 days, 799 (79.7 %) patients were still actively partic-
ipating. SWITCO65? is a unique opportunity to study
short- and long-term outcomes in elderly patients with
VTE. The Steering Committee encourages national and
international collaborative research projects related to
SWITCO65?, including sharing anonymized data and
biological samples.
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Introduction
Acute venous thromboembolism (VTE), defined as deep
vein thrombosis (DVT) and/or pulmonary embolism (PE),
is a common disease and has a high impact on morbidity,
mortality, and costs of care [1]. The annual incidence of
VTE rises exponentially with age, from \1 case per 1,000
person-years in persons aged below 50 years to more than
6 cases per 1,000 person-years in persons aged above
80 years [2–5]. Overall, 60 % of VTE cases occur in
individuals aged C65 years [1, 6].
Switzerland and other Western countries are facing a
rapidly aging population [7]. Extrapolations from the Swiss
Federal Statistical Office indicate that the proportion of
persons aged over 65 years will increase from 17 % in
2008 to 28 % in 2060 [8]. The incidence and health burden
of VTE is likely to increase with the expected growth of the
elderly population [9].
Despite the significant public health impact of VTE in
the elderly and growing evidence that VTE may have a less
favourable course in elderly patients (e.g., higher recur-
rence, bleeding, and mortality rates) [6], older patients are
underrepresented in randomized and nonrandomized pro-
spective studies of VTE [10, 11]. To date, little is known
about the factors that determine medical outcomes, quality
of life, and costs of care in the elderly with VTE. To fill
this gap of knowledge, the National Institute of Health and
international experts in the field called for VTE-related
research in elderly patients [1, 12–14]. A prospective
cohort study with long-term follow-up is the best meth-
odological approach to examine the impact of risk factors
and processes of care on patient outcomes because random
assignment of risk factors is neither feasible nor ethical.
Therefore, a group of academic investigators set up the
Swiss Cohort of Elderly Patients with VTE (SWIT-
CO65?), a prospective multicenter cohort study of in- and
outpatients aged 65 years or older with acute VTE from
university and non-university hospitals in Switzerland. The
goal of SWITCO65? is to examine which clinical and
biological factors and processes of care drive short- and
long-term medical outcomes, health-related quality of life,
and medical resource utilization in elderly patients with
acute VTE. In this paper, we describe the study rationale,
methods, and the patient population of SWITCO65?.
Methods
Study design
SWITCO65? is a prospective multicenter cohort study of
in- and outpatients aged 65 years or older with acute VTE
from all five university (Basel, Bern, Geneva, Lausanne,
and Zurich) and four high-volume non-university hospitals
(cantonal hospitals of Baden, Frauenfeld, Luzern, and St.
Gallen) in Switzerland. Only hospitals with [250 beds
were considered to optimize enrollment of patients with
VTE within sites and minimize the total number of hos-
pitals required. The Ethics Committee at each participating
center approved the study. SWITCO65? is entirely funded
by grants from the Swiss National Science Foundation
(grant no. 33CSCO-122659/139470).
Patients sample
Patients were recruited from September 2009 to March 2012.
Study nurses identified potential study subjects with VTE in
the in- and outpatient services of all participating study sites.
Consecutive patients aged 65 years or older with objectively
diagnosed, symptomatic DVT or PE were eligible. Symp-
tomatic DVT was defined as an acute onset of leg pain or
swelling plus incomplete compressibility of a venous segment
on ultrasonography or an intraluminal filling defect on con-
trast venography [15]. Because iliac veins and the inferior
vena cava may be technically difficult to compress, additional
diagnostic criteria for iliac and caval DVT also included
abnormal duplex flow patterns compatible with thrombosis or
an intraluminal filling defect on spiral computed tomography
or magnetic resonance imaging venography [16–18]. Given
that compression ultrasonography has a lower sensitivity and
specificity for distal DVT [19], patients with isolated distal
DVT were eligible only if the incompressible distal vein
transverse diameter was at least 5 mm [20].
Symptomatic PE was defined as a positive spiral com-
puted tomography or pulmonary angiography, a high-
probability ventilation-perfusion scan, or proximal DVT
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documented by compression ultrasonography or contrast
venography in patients with acute chest pain, new or
worsening dyspnea, hemoptysis, or syncope [21, 22].
Exclusion criteria were inability to provide informed
consent (i.e., severe dementia), conditions incompatible
with follow-up (i.e., terminal illness or place of living too
far away from the study center), insufficient German or
French-speaking ability, thrombosis at a different site
than lower limb, catheter-related thrombosis, or previous
enrollment in the cohort.
Eligible patients who had no exclusion criteria were
approached for informed consent to participate in the study.
Because of collection and storage of biologic samples
(including genetic material), patients were separately asked
permission for future uses of these samples for genetic
analyses related to VTE, with the specification that the
investigators must obtain specific consent for any future
use that is unrelated to VTE (tiered consent) [23]. Patients
who initially refused participation because they were
unwilling to come regularly back to the hospital for follow-
up visits were offered home visits.
Follow-up visits
Follow-up includes one telephone interview and two sur-
veillance face-to-face evaluations during the first year of
study participation and then semi-annual contacts, alter-
nating between face-to-face evaluations (clinic visits or
home visits in house-bound patients) and telephone calls as
well as periodic reviews of the patient’s hospital chart
(Table 1). During each visit/contact, study nurses interview
patients to obtain information about the date and type of
clinical events (recurrent VTE, bleeding, and death). If a
clinical event has occurred, this information is comple-
mented by reviewing medical charts and interviewing
patients’ primary care physicians and family members.
During the baseline assessment and surveillance clinic
visits, participants also undergo a brief clinical examina-
tion and generic and disease-specific quality of life
assessments.
Study nurses at each study site prospectively collect
clinical data, diagnostic and therapeutic processes of care,
laboratory parameters, and information about health-related
quality of life for all enrolled patients using standardized
data collection forms (Table 2). In non-enrolled patients,
anonymized demographic data were collected to assess the
risk of a potential patient selection bias. The follow-up
period will continue until December 2013.
Outcomes
The primary medical outcome is the recurrence of symp-
tomatic, objectively confirmed VTE during the follow-up
period, defined as new or recurrent PE or DVT (proximal
and/or distal) based on previously published criteria
[22, 24].
Secondary medical outcomes are the occurrence of
major bleeding, all-cause mortality, and the postthrombotic
syndrome (PTS) during the follow-up period [25–27]. We
defined major bleeding as a fatal bleeding, a symptomatic
bleeding in a critical organ (intracranial, intraspinal,
intraocular, retroperitoneal, intraarticular, pericardial, or
Table 1 Data collection and follow-up schedule
Data Collection Study month
Baseline 3 6 12 18 24 30 36 42 48
Type of assessment
Face-to-face evaluation (at the hospital or during a home visit) X X X X X X
Telephone interview X X X X
Review of the patient’s hospital chart X X X X X X X X X X
Parameter
Patient baseline characteristics X
Initial VTE-related processes of care X X
Assessment of VTE recurrence, bleeding, and death X X X X X X X X X
Generic and disease-specific HRQL assessment X X X X X X
Symptoms and signs of the PTS X X X X X X X X X
Blood sampling X X
Leg vein ultrasonography (in patients with index DVT only) X
Echocardiography (in patients with index PEonly) X
Medical resource utilization X X X X X X
VTE venous thromboembolism, HRQL health-related quality of life, PTS postthrombotic syndrome, DVT deep vein thrombosis, PE pulmonary
embolism
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intramuscular with compartment syndrome), a bleeding
with a reduction of hemoglobin C20 g/l, or a bleeding
leading to the transfusion C2 units of packed red blood
cells [25]. We also collect information on all bleeding
events that require medical attention (e.g., a physician
consultation or a visit at the emergency department).
The PTS is defined as a score of C5 based on the Villalta
scale [26]. The Villalta scale is well validated [28], has
good to excellent inter-observer reliability [29], and is
responsive to clinical change [31, 32].
We assess outcomes using patient or proxy interviews,
interview of the patient’s primary care physician, and/or
hospital chart review. A committee of three blinded clinical
experts adjudicates all outcomes and classifies the cause of
all deaths as definitely due to PE, possibly due to PE, due to
major bleeding, or due to another cause [25, 30]. Final
classifications are made on the basis of the full consensus
of this committee.
Study nurses collect clinical patient variables and screen for
the presence of the PTS using the Villalta scale (Table 2) [27].
Study nurses also collect information on initial VTE-related
processes of care that potentially have an impact on medical
and economic patient outcomes [31–34], including diagnostic
strategy used to diagnose VTE, anticoagulation-related prac-
tices, prescription of compression stockings in patients with
DVT, and invasive treatments (systemic thrombolysis, catheter-
based interventions, insertion of a vena caval filter, or sur-
gical thromboembolectomy) [32]. To determine direct costs
of medical care, study nurses collect detailed information
about patients’ demographic and socioeconomic factors,
VTE-related risk factors, history and physical examination,
bleeding risk factors, initial VTE-related processes of care,
VTE-related complications, symptoms and signs of the PTS,
and health-related quality of life. Utilized resources will be
transformed in cost measures using Swiss insurance reimburse-
ment standards (www.tarmedsuisse.ch; www.swissdrg.ch).
Laboratory variables
At the time of study enrolment, information on routine
laboratory tests (blood count, serum chemistry, and basic
Table 2 Data collected
Data collected Variables
Patient baseline characteristics
Demographic and socioeconomic
factors
Age, gender, race, education level, and insurance and living status
VTE-related risk factors Recent immobilization, cancer, prior VTE, estrogen therapy, known thrombophilia, arterial
hypertension, smoking, physical activity, acute heart failure, recent sepsis, acute respiratory failure,
acute rheumatic disease, recent stroke, recent major surgery, inflammatory bowel disease, and
family history of VTE
History and physical examination VTE-related symptoms, vital parameters, signs and symptoms of the PTS [27], and
electrocardiographic findings
Bleeding risk factors History of stroke, history of gastrointestinal bleeding, history of major bleeding, recent myocardial
infarction, diabetes mellitus, renal failure, anemia, thrombocytopenia, liver disease, and
concomitant use of antiplatelet treatment
VTE event Type (DVT and/or PE) and localization
Initial VTE-related processes
of care
Diagnostic strategy, type of treatment
VTE-related complications VTE recurrence, bleeding event (minor, major), mortality, chronic thromboembolic pulmonary
hypertension, heparin-induced thrombocytopenia, and signs and symptoms of the PTS [27]
Generic and disease specific
health-related quality of life
Short Form 36 Health Survey Questionnaire (SF-36), VEINES quality of life and symptom severity
[VEINES-QOL/Sym] questionnaire for patients with symptomatic index DVT and the Pulmonary
Embolism Quality of Life [PEmb-QoL] questionnaire for patients with symptomatic index PE
Leg vein ultrasonography Signs of residual vein thrombosis [46]
Echocardiography Signs of right-ventricular dysfunction [47, 48]
Blood collection Hemostasis tests, biomarkers, DNA and RNA analysesa
Medical resource utilization VTE-related processes of care, length of the index hospitalization, number of VTE-related physician
and emergency department visits, acute and chronic care hospital and nursing home admissions
VTE venous thromboembolism, PTS postthrombotic syndrome, DVT deep vein thrombosis, PE pulmonary embolism
a At baseline: D-dimer ELISA (Vidas), fibrinogen, factor V Leiden mutation, prothrombin G20210A mutation, N-terminal pro-brain natriuretic
peptide, genotyping cytochrome P450 2C9 (CYP2C9), genotyping vitamin K epoxide reductase complex subunit 1 (VKORC1), ultra sensitive
troponin, ultra sensitive C-reactive protein; at 12 months after the index VTE: D-dimer ELISA (Vidas), fibrinogen, antithrombin, protein C,
protein S, lupus anticoagulant, anti-beta-2-glycoprotein antibodies, anticardiolipin antibodies, homocystein, factor VIII, factor IX, factor XI
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coagulation studies, such as the international normalized
ratio) was collected and a baseline blood sample was drawn
from each consenting patient. The blood samples were
locally processed, packed in dry ice, and sent to the
SWITCO65? project biobank where the samples are stored
in a -80 C high capacity freezer.
Because fibrinogen, antithrombin, protein C and S,
antiphospholipid antibodies, and factor VIII, IX, and XI
levels may be influenced by the presence of acute throm-
bosis or ongoing anticoagulation, these parameters are
measured in a second fasting blood sample at 12 months
after the index VTE. In patients who are still receiving
vitamin K antagonists at that time, vitamin-K dependant
coagulation factors (protein C and S, factor IX) are not
measured. Low levels of coagulation inhibitors (anti-
thrombin, protein C or S) and the presence of anti-
phospholipid antibodies are confirmed in a second blood
sample. In total, the SWITCO65? biobank contains
105 ml blood from each participant. All individual labo-
ratory tests are performed in a single reference laboratory
(Table 2).
A biobank has been established to collect and store
serum, plasma, and DNA and RNA samples to explore
future, yet unknown biological prognostic markers for VTE
and treatment responses. To ensure optimal sample storing
and processing, our study biobank follows established
quality standards [35].
Additional imaging exams
Patients with symptomatic PE underwent transthoracic
echocardiography at baseline to assess the presence of right
ventricular dysfunction, a parameter that is associated with
increased overall mortality following PE [36]. On-site
cardiologists performed echocardiographic exams accord-
ing to a standardized protocol.
Because residual vein thrombosis is known to be a risk
factor of VTE recurrence [37], each patient with symp-
tomatic proximal DVT had a leg vein ultrasonography
based on a standard protocol at three months after enrol-
ment. On-site vascular physicians performed all exams
according to a standardized protocol.
Health-related quality of life assessment
We assess patients’ generic health-related quality of life at
baseline and during follow-up using the standard Short
Form 36 Health Survey Questionnaire. We evaluate disease-
specific health-related quality of life using validated ques-
tionnaires: the VEINES quality of life and symptom
severity (VEINES-QOL/Sym) questionnaire for patients
with symptomatic index DVT and the Pulmonary Embolism
Quality of Life (PEmb-QoL) questionnaire for patients with
symptomatic index PE [38, 39]. All questionnaires are self-
administered.
Sample size calculation and planned statistical analyses
We based our sample size calculation on the clinical rel-
evance of risk factors for VTE recurrence. A risk factor
was considered clinically relevant if its prevalence is
C10 % in elderly patients with VTE and if this risk factor
increases the risk of recurrent VTE by C2-fold during a
4-year follow-up period [40]. Assuming a conservative
baseline VTE recurrence rate of 15 % at four years, a
sample size of C649 elderly patients with VTE was needed
to detect a hazard ratio of C2.0 for VTE recurrence, using a
80 % power and a 2-sided alpha level of 0.05 [41–43].
Estimating that up to 30 % of patients would die from non-
VTE-related causes or drop out for other reasons during the
4-year follow-up, an initial sample size of about 1,000
patients was necessary.
The cumulative incidence of recurrent VTE will be
calculated by Kaplan–Meier survival analysis. The Cox-
proportional hazards model will be used to evaluate the
association between clinical, biological, and radiographic
predictors and the time of VTE recurrence. To account for
clustering of patients within a given center, we will include
a fixed-center effect in the Cox-proportional hazard model.
We will use the same survival methods to evaluate the
association between predictors and major bleeding, death,
and the PTS.
Mean scores for the SF-36, VEINES-QOL/Sym, and
PEmb-QoL questionnaire will be computed at baseline, at
3, 12, 24, 36, and 48 months. Differences in mean scores
over time will be analyzed using repeated-measures anal-
ysis of variance. Proportions of patients who worsened
from the previous time point will be calculated. Potential
determinants (clinical patient factors, processes of care) of
worsening health-related quality of life scores from 3, 12,
24, 36, and 48 months will be evaluated using logistic
regression, with the change in score (dichotomized as
improved versus worse) as the dependent variable.
To account for differences in follow-up time, costs of
care for each patient will be expressed as annualized costs
and weighted for the number of months a given patient was
observed. A linear regression model will be used to study
the association between costs of care and clinical patient
factors, processes of care, and medical outcomes.
Preliminary results
Between September 8, 2009, and March 31, 2012, a total of
1,863 patients with VTE were screened (Fig. 1). We
excluded 462 (24.8 %) who had at least one of the
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following exclusion criteria: inability to provide informed
consent (n = 285), follow-up not possible (n = 192),
insufficient ability to speak German or French (n = 51),
thrombosis at different site than lower limb (n = 21), or
catheter-related thrombosis (n = 7), leaving a sample of
1,401 eligible patients. After the exclusion of 398 patients
who refused to provide informed consent, our initial study
sample comprised 1,003 patients (53.8 % of initially
screened patients). The baseline characteristics of the
study sample are shown in Table 3. Non-enrolled patients
were statistically significantly older (mean age 78 vs.
76 years; P = 0.001), more likely to be women (59 vs.
47 %; P \ 0.001), and were somewhat less likely to have
symptomatic PE (65 vs. 69 %; P = 0.053) than enrolled
patients.
By October 16, 2012, six patients had withdrawn their
consent and did not allow the use of their data. Of the 997
remaining patients, after an average follow-up time of
512 days, 799 (79.7 %) patients were still actively partic-
ipating, 150 (15 %) had died, 47 (4.7 %) had withdrawn
their consent allowing the use of their data and one (0.1 %)
had been lost to follow-up. The 53 patients who withdrew
their consent were statistically significantly more likely to
be women (68 vs. 46 %; P = 0.003) and had a significantly
longer length of hospital stay (15.8 vs. 9.4 days;
P \ 0.001) than the 950 patients who continued partici-
pating, was lost to follow-up or who died.
The enrolment of new patients was terminated on March
31, 2012 when the targeted patient sample size was
achieved. Of the 1,003 initially enrolled patients, the
majority (51.7 %) is aged C75 years and 52.7 % are men
(Table 3). Virtually all patients are Caucasians (99.8 %).
Patients from all educational levels are well represented in
the study. A substantial proportion of patients has comor-
bid diseases, such as active cancer, chronic lung disease, or
heart failure. Overall, 69.3 % of patients had PE with or
without DVT. Most patients (81.2 %) were treated in the
hospital. Overall, 48.6 % of patients received low-molecular-
weight heparin as initial antithrombotic treatment.
The vast majority of patients completed the baseline
SF-36 (89.9 %), VEINES-QOL/Sym (88.7 %), and PEmb-
QoL (86.2 %) questionnaires. Baseline blood samples are
available in 905 (90.9 %) of enrolled patients. Overall data
completeness is excellent, with less than 5 % missing
values.
Discussion
The SWITCO65? study is a multicentre prospective
cohort aiming to study which clinical and biological pre-
dictors and processes of care drive long-term medical
outcomes, quality of life, and medical resource utilization
in 1,003 elderly patients with acute VTE. After an average
follow-up time of 512 days, 799 (79.7 %) patients were
still actively participating.
Our cohort study has several strengths. First, given the
high incidence of VTE and the lack of data for elderly
patients with VTE, a cohort project focusing on the out-
comes of elderly patients with VTE is innovative and rel-
evant from a public health point of view. To our
knowledge, our cohort study is the most comprehensive
attempt to study the impact of clinical, biological, and
radiologic predictors on clinically relevant outcomes,
health-related quality of life, and medical resource utili-
zation in elderly patients with VTE. Second, a particular
Fig. 1 Flow chart
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strength is the focus on health-related quality of life mea-
sures. Given their reduced life expectancy, health-related
quality of life aspects may be particularly relevant in the
elderly. Third, because factors that drive medical resource
utilization have not been prospectively examined in elderly
patients with VTE, our cohort will improve our under-
standing of what drives cost of care in such patients.
Fourth, we have established a biobank including DNA and
RNA samples. These samples can be used to study future,
yet unknown predictors of VTE-related prognosis. Fifth,
SWITCO65? benefits from a professional data manage-
ment that includes central monitoring and regular data
quality control measures. Further strengths are the low
dropout rate of 4.8 % and the near-complete data collection.
Our study has several potential limitations. First, our
study patients were recruited at all five Swiss university
hospitals (two of which serve also as community hospital)
and four high-volume non-university hospitals and there-
fore, our cohort is not entirely population-based. Given the
decentralized structure of the Swiss health care system, the
high complexity and costs of baseline and follow-up
assessments, a broader recruitment at small-volume hos-
pital sites, would not have been logistically and financially
feasible. However, because we included consecutive VTE
patients from in- and outpatient services at university and
non-university hospitals, we believe our study sample to be
fairly representative for Swiss patients with VTE. Second,
although we offered home visits and enrolled patients with
mild to moderate cognitive disorders, we cannot exclude
the possibility that the sickest patients are underrepresented
in our cohort because patients suffering from severe demen-
tia or terminal illness were excluded from participation.
Another common reason for non-enrollment was refusal to
participate (21.4 % of screened patients), most probably
because of the high number and complexity of baseline and
follow-up assessments, a known obstacle to study partici-
pation in the elderly [44]. However, given the high study
burden, the 53.8 % enrollment rate that we achieved is
laudable for a prospective cohort study focusing on elderly
patients and compares well with other cardiovascular cohort
studies of older persons. For example, the Cardiovascular
Health Study enrolled 39.6 % of elderly subjects with
whom contact was made [45]. Third, 99.8 % of our study
patients were Caucasians. Thus, our results may not be
generalizable to other racial or ethnic groups. Finally,
because the present paper focuses on the study rationale and
methods and the follow-up is still ongoing, we did not
present medical outcome data.
All data are centrally managed and stored at the Clinical
Trials Unit of the University of Bern, Switzerland. The study
biobank is located at the Service and Central Laboratory of
Hematology at the Lausanne University Hospital, Lausanne,
Switzerland. Additional information about the cohort, such
as the study protocol, data collection forms, study progress,
ongoing nested projects, and planned or published articles,
can be found on the study website (www.switco65.ch) or at
ClinicalTrials.gov (identifier NCT00973596). The Steering
Committee of SWITCO65? encourages national and inter-
national collaborative research projects related to SWIT-
CO65?, including sharing anonymized data and biological
samples. All submitted projects are peer-reviewed and sub-
ject to a final decision by the Steering Committee based on
Table 3 Baseline characteristics of the full cohort
Characteristics n/N (%)a
Male gender 529/1003 (52.7)
Age, years
65–75 484/1003 (48.3)
75–85 385/1003 (38.4)
[85 134/1003 (13.4)
Caucasian race 994/996 (99.8)
Education level
Less than high school 547/992 (55.1)
High school graduate 252/992 (25.4)
University graduate 193/992 (19.5)
Living status
At home with someone else 631/994 (63.5)
At home alone 339/994 (34.1)
In nursing home 24/994 (2.4)
Comorbid diseases
Active cancerb 157/995 (15.8)
Chronic lung disease 136/995 (13.7)
Heart failure 77/995 (7.7)
Prior history of VTE 283/995 (28.4)
Index VTE event
DVT only 308/1003 (30.7)
PE only 558/1003 (55.6)
Both DVT and PE 137/1003 (13.7)
Site of treatment
Inpatientc 802/995 (81.2)
Outpatient 187/995 (18.8)
Initial treatment
Low-molecular-weight heparin 468/960 (48.7)
Unfractionated heparin 332/960 (34.6)
Fondaparinux 159/960 (16.6)
Danaparoid 1/960 (0.1)
VTE venous thromboembolism, DVT deep vein thrombosis, PE pul-
monary embolism
a Denominators are changing because the information was not
available in all patients
b Defined as cancer that required therapy (surgery, chemotherapy,
and/or radiotherapy) during the last 3 months
c Overall, 184 inpatients developed VTE during a hospitalization for
another reason
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the following criteria: (1) ethical considerations, (2) origi-
nality, (3) validity of the methods used, and (4) feasibility.
Any requests for access to SWITCO65? data or material are
to be submitted to the Steering Committee using the study
Subproject Proposal Form (available at www.switco65.ch).
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